APA (7th ed.) Citation

Gottschling, S., Herpel, E., Eberhardt, W. E. E., Köhne, C., Kuhnt, T., Muley, T., . . . Penzel, R. (2012). The gefitinib long-term responder (LTR) - a cancer stem-like cell story?: Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP). Lung cancer, 77(1), . https://doi.org/10.1016/j.lungcan.2012.03.003

Chicago Style (17th ed.) Citation

Gottschling, Sandra, et al. "The Gefitinib Long-term Responder (LTR) - a Cancer Stem-like Cell Story?: Insights from Molecular Analyses of German Long-term Responders Treated in the IRESSA Expanded Access Program (EAP)." Lung Cancer 77, no. 1 (2012). https://doi.org/10.1016/j.lungcan.2012.03.003.

MLA (9th ed.) Citation

Gottschling, Sandra, et al. "The Gefitinib Long-term Responder (LTR) - a Cancer Stem-like Cell Story?: Insights from Molecular Analyses of German Long-term Responders Treated in the IRESSA Expanded Access Program (EAP)." Lung Cancer, vol. 77, no. 1, 2012, https://doi.org/10.1016/j.lungcan.2012.03.003.